Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 3/20 | 0.36 |
| ▸ | FPR1 | P21462 | 6/20 | 0.35 |
| ▸ | FPR2 | P25090 | 5/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886406 | 0.79 | GPBAR1 (0.49) | GPBAR1ADRA1AADRA1DADRA1BADRA2A | |
| SCHEMBL3889971 | 0.79 | GPBAR1 (0.67) | GPBAR1LMNA | |
| SCHEMBL4324693 | 0.76 | ROCK1 (0.54) | GPBAR1CYP3A4 | |
| SCHEMBL3860919 | 0.76 | ROCK1 (0.54) | CYP3A4 | |
| SCHEMBL3887155 | 0.76 | LRRK2 (0.43) | GPBAR1CYP3A4 | |
| SCHEMBL3887046 | 0.76 | JAK2 (0.40) | GPBAR1CYP3A4 | |
| SCHEMBL3884454 | 0.67 | ROCK1 (0.41) | — | |
| SCHEMBL4322087 | 0.65 | MAPK1 (0.41) | GPBAR1ADRA1AADRA1DADRA1BADRA2A | |
| SCHEMBL3884743 | 0.65 | ROCK1 (0.59) | GPBAR1ADRA1AADRA1DADRA1BP2RX7 | |
| SCHEMBL3889088 | 0.65 | GPBAR1 (0.53) | GPBAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080058384-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058384-A1 | Novel Compounds | ARHGDIB, TNK2, ROCK2 | GPBAR1 2826/4885ADRA1A 3436/4885ADRA1D 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.